TrialInvestigational new drugs2024

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.

Elisabeth I Heath et al.PubMed ↗Publisher ↗

No numbers read from the abstract.